2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

322. Hemophilia A and B: Clinical and Epidemiological: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, Gene Therapy, Women’s Health, Artificial Intelligence (AI), Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality Improvement, Systems-Based Hematology, Diseases, Bleeding and Clotting, Hemophilia, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Study Population, Human, Adult, Young Adult, Animal Model
PAPER

3045 Results from the ESSENCE study demonstrate low prevalence of synovitis and low bleeding rates under emicizumab in patients > 12 years

Barbara Zieger, MD, Christoph Königs, MD, PhD2, Nikola Hagedorn, MD3, Swee Wenning, MD4, Annalena Hlinka, MD5, Susan Halimeh, PhD6, Martin Olivieri, MD7, Kai Gutensohn8, Wolfgang Miesbach, MD9, Sabrina Fehrenbach, PhD10, Michael Sigl-Kraetzig, MD11, Johannes Oldenburg, MD12
1 Universitätsklinikum Freiburg, Kinder- und Jugendklinik, Freiburg i. Br., Germany
2 Goethe-Universität, Frankfurt a. M., Germany
3 Charité Universitätsmedizin, Berlin, Germany
4 SRH Kurpfalzkrankenhaus Heidelberg GmbH, Heidelberg, Germany
5 Universitätsklinikum Düsseldorf, Düsseldorf, Germany
6 Gerinnungszentrum Rhein-Ruhr, Duisburg-Altstadt, Germany
7 Dr. von Hauner Children’s Hospital, LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany
8 Werlhof Institut, Hannover, Germany
9 Universitätsmedizin Frankfurt, Frankfurt a. M., Germany
10 Roche Pharma AG, Grenzach-Wyhlen, Germany
11 Institut für pädiatrische Forschung und Weiterbildung, Blaubeuren, Germany
12 Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany

Background: Prophylaxis with emicizumab has significantly improved bleeding outcomes in patients with hemophilia A (HA) as demonstrated in the HAVEN clinical trial program. However, long-term joint health, specifically the prevalence of synovitis — a primary driver of hemophilic arthropathy — requires further characterization in real-world clinical practice. Current data only give a broad range of prevalence about 10 to 86% (S2k-Guideline, Synovitis in patients with hemophilia, 2022). The ESSENCE study evaluates the prevalence of clinically relevant synovitis in knee, ankle and elbow joints in patients with moderate and severe HA under treatment with emicizumab veri?ed by ultrasound (US) and magnetic resonance imaging (MRI) and respective scores.

Methods: This multicenter, retrospective study (ESSENCE, DRKS-ID: DRKS00036847) analyzed data from 45 male patients with moderate or severe HA (moderate: n= 12; 26.7% or severe: n= 33; 73.3%) across 10 specialized hemophilia care centers in Germany. Ten out of 45 (22.2%) patients had an inhibitor history. Eligible patients were aged 12 years and older (median age: 29 years, range 12 to 67 years) and had received emicizumab prophylaxis for at least 6 months. Joint evaluations during the last year of the observation period focused on the primary affected joints: ankles, knees, and elbows (total of 270 joints evaluated; 90 of each type). Imaging modalities, including US and MRI, were utilized based on institutional protocols. Statistical analyses are based on final data with data cut-off 24 July 2026.

Results: Overall, a low prevalence of synovitis was observed in 2024, the last year of the observation period, with 20.0% (9/45) of patients experiencing at least one synovitis occurrence (ongoing or newly diagnosed). Prevalence was similar across age groups: 16.7% (2/12) in patients aged 12–17 years and 21.2% (7/33) in patients aged ≥18 years. At the individual joint level, the overall prevalence of synovitis was low at 4.8% (13 of 270 scanned joints). Joint-specific analysis revealed a synovitis prevalence of 4.4% in ankles (4 of 90) and 10% in knees (9 of 90), while no synovitis was detected in the elbows. Four out of 45 patients (8.9%) had a newly diagnosed synovitis during 2024, thereof 1 in the ankle and 3 in the knee. Of these 4 patients, 3 experienced synovitis lasting longer than 6 months. Further, 1 patient was treated with emicizumab for 6 to 12 months and 3 patients for more than 12 months.

Patients under long-term emicizumab treatment, with 95.6% of patients being treated for more than 12 months, exhibited low joint bleeding rates in ankles, knees and elbows (median spontaneous JABR: 0.0 [range 0;0] for ankles, 0.0 [range 0;6] for elbows, and 0.0 [range 0;2] for knees) during 2024, the last year of observation.

Imaging was performed in a high proportion of the cohort, with 23 patients receiving US and 9 undergoing MRI. Out of 195 total scanned joints with US, 81.6% were evaluated as part of routine clinical surveillance. US confirmed synovitis in 9 examinations (6 suspected based on symptoms, 3 identified during routine clinical surveillance). MRI confirmed 1 out of 1 clinically suspected case. Overall, 7 of the total 10 confirmed imaging findings were clinically suspected prior to imaging, while 3 of 10 were incidental findings discovered during clinical routine scans.

Conclusions: Patients with moderate or severe HA under emicizumab prophylaxis in Germany exhibit a very low prevalence of synovitis alongside highly effective bleeding control. This is in line with earlier findings on bleeding control and joint health in patients with HA treated with emicizumab in clinical trials and real-world studies (HAVEN 3: Kiialainen A et al. Blood 2019; BEYOND ABR: Kruse-Jarres R et al. Blood 2025; real-world: Vagrecha A et al. Blood 2020; Arcudi S et al. Blood 2021). Furthermore, point-of-care ultrasound (POCUS) is well-established across German hemophilia care centers and serves as a highly effective tool for both confirming suspected cases and detecting subclinical synovitis during routine clinical follow-up.

Johannes Oldenburg, MD: Bayer - Honoraria; LFB - Honoraria; Takeda - Honoraria; Bayer, Biotest, CSL Behring, NovoNordisk, Octapharma, Pfizer, Roche, SOBI and Takeda - Honoraria; Freeline - Honoraria; Biomarin - Honoraria; Swedish Orphan Biovitrum - Honoraria; Octapharma - Honoraria; Novo Nordisk - Honoraria; Biogen Idec - Honoraria; Sanofi - Honoraria; Chugai - Honoraria; CSL Behring - Honoraria; Grifols - Honoraria; Pfizer - Honoraria; Biotest - Honoraria; SOBI - Honoraria; Roche - Honoraria; Spark Therapeutics - Honoraria; Biotest - Research Funding; CSL Behring - Research Funding; Takeda - Research Funding; Bayer - Research Funding; Octapharma - Research Funding; Swedish Orphan Biovitrum - Research Funding; Novo Nordisk - Research Funding; Bayer, Biotest, CSL Behring, NovoNordisk, Octapharma, Pfizer, Roche, SOBI and Takeda - Research Funding; Spark Therapeutics - Research Funding; Pfizer - Research Funding; Biogen Idec - Research Funding; Freeline - Research Funding; SOBI - Research Funding; Bayer, Biotest, CSL Behring, NovoNordisk, Octapharma, Pfizer, Roche, SOBI and Takeda - Patents & Royalties; Bayer - Consultancy (Includes expert testimony); Freeline - Consultancy (Includes expert testimony); Biotest - Consultancy (Includes expert testimony); CSL Behring - Consultancy (Includes expert testimony); SOBI - Consultancy (Includes expert testimony); Swedish Orphan Biovitrum - Consultancy (Includes expert testimony); Biomarin - Consultancy (Includes expert testimony); Grifols - Consultancy (Includes expert testimony); Chugai - Consultancy (Includes expert testimony); LFB - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Bayer, Biotest, CSL Behring, NovoNordisk, Octapharma, Pfizer, Roche, SOBI and Takeda - Consultancy (Includes expert testimony); Spark Therapeutics - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Octapharma - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Biogen Idec - Consultancy (Includes expert testimony); Novo Nordisk - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony)